Contact Supplier

Contact Supplier

To get in touch with ARTES Biotechnology GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    ARTES presenting innovative vaccine technologies at BIO-Europe Munich

    news-releasesARTES Biotechnology GmbH
    October 27th 2023

    Langenfeld, Germany: – ARTES Biotechnology, the German-based biopharmaceutical CRO specializing in development of recombinant proteins, will once again participate in Europe’s leading life sciences partnering conference, BIO-Europe 2023, this year in Munich.

    ARTES will be an exhibitor at the event with a stand at Booth 213 at Munich’s Trade Fair Center, displaying its range of CRO business offer and solutions for difficult to express recombinant proteins as well as for the development of production processes.

    Innovative technologies

    ARTES is expert in the field of developing microbial cell lines and the corresponding processes for targets of clients’ choice, that can be a vaccine, a biopharmaceutical, a biosimilar and/or enzyme. Another part of the business is the portfolio of ready-to-transfer processes.

    All platform technologies (cell lines and antigen presentation) ensure freedom-to-operate and are protected by patents and trade secrets. ARTES is available to negotiate exclusive license terms.

    ARTES Managing Director Dr, Michael Piontek and Technology Director Dr. Volker Jenzelewski will lead the ARTES presence on stand and at partnering meetings, including on digital manifestation of BIO-Europe on November 14-15.

    The team will be able to share information on numerous exciting developments at ARTES.

    About ARTES Biotechnology

    ARTES Biotechnology GmbH is a Germany-based company specialized in development of recombinant protein production processes from microbial expression systems. The offer is particular in the development of optimized production cell lines and processes based on yeast (Hansenula, Pichia, Saccharomyces) and bacteria (E. coli). The expression platform is complemented by a unique virus-like particle (VLP) technology for antigen presentation and vaccine development. For more than 20 years, ARTES partners successfully with human and animal health companies, enzyme manufacturer, the cosmetic, diagnostic and nutrition industry. Operation worldwide takes place from its 870 sqm facilities in Langenfeld.

    About BIO-Europe 2023

    BIO-Europe® is a premier partnering conference that annually attracts an international “who’s who” of decision makers from Europe’s biotech, pharma and investment communities for high caliber networking.

    The three-day 2023 event opens November 6 at the Messe München Trade Fair Center in Munich, with a further digital partnering event scheduled for November 14-15.

    Featuring a sophisticated partnering system, partneringONE®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.

    The event is expected to involve up to 5,500 potential partners, with a conference agenda structured around the headline themes of Partnering and Investment Trends, Therapeutics Insights, and Ecosystem Innovation. The program also features more than 20 workshops and panels, with thousands of licensing opportunities posted.

    The event is organized by Informa Connect with more information at:


    Click on ARTES Biotechnology  to see introductory video of the VLP technology platform made with ARTES.


    ARTES Biotechnology is a globally working, well established and reliable technology provider for recombinant protein production.

    ARTES presenting innovative vaccine technologies at BIO-Europe Munich

    Contact ARTES Biotechnology GmbH

    Simply fill out the form below to contact ARTES Biotechnology GmbH now.

    Send ARTES Biotechnology GmbH a Message